Home › Non-Small Cell Lung Cancer › Washington › Vancouver
Non-Small Cell Lung Cancer clinical trials in Vancouver, WA
9 studies for Non-Small Cell Lung Cancer are looking for participants at sites in and around Vancouver (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
RecruitingPhase 3
- Compass Oncology, Vancouver
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
RecruitingPhase 3
- Northwest Cancer Specialists, P.C., Vancouver
A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
RecruitingPhase 2/3
- Northwest Cancer Specialists - Vancouver /ID# 277855, Vancouver
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
RecruitingPhase 3
- Northwest Cancer Specialists PC, Vancouver
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
RecruitingPhase 3
- Research Site, Vancouver
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
RecruitingPhase 3
- Clinical Study Site, Vancouver
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
RecruitingPhase 2/3
- USOR - Northwest Cancer Specialists, P.C. dba Compass Oncology - Vancouver Cancer Center, Vancouver
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
RecruitingPhase 3
- USO - Northwest Cancer Specialists, Vancouver
MYLUNG Consortium Part 3: Observational Study
RecruitingObservational study
- Northwest Cancer Specialists, P.C., Vancouver
Non-Small Cell Lung Cancer trials in other cities
- Houston, TX145 studies
- New York City, NY120 studies
- Arlington, VA104 studies
- Nashville, TN96 studies
- Boston, MA89 studies
- Los Angeles, CA87 studies
- St. Louis, MO71 studies
- Chicago, IL61 studies
- Baltimore, MD60 studies
- San Antonio, TX59 studies
- Columbus, OH55 studies
- Washington, DC54 studies
Other studies in Vancouver
- Lung Cancer7 studies
- Colorectal Cancer6 studies
- Metastatic Cancer4 studies
- Pancreatic Cancer4 studies
- Prostate Cancer4 studies
- Breast Cancer4 studies
- Ulcerative Colitis3 studies
- Crohn's Disease3 studies
- Cancer (all types)3 studies
From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.